CDK inhibitors as potential therapeutics for ER+/ and/or Her2+ bc

Hopeful · 12-08-2009, 07:51 AM

http://breast-cancer-research.com/co...df/bcr2454.pdf

Hopeful

Rich66 · 12-08-2009, 01:57 PM

Looks like CDK inhibitors are still in early trials? I like the idea of synergy with Tamoxifen and Herceptin. Considering Tamoxifen can affect both Er+ and ER-, could be a great lower toxicity approach. Amen.

Hopeful · 12-08-2009, 02:30 PM

The one they reference in the editorial is PD 0332991. Pfizer is currently testing it with letrozole, but only in ER+ Her2- patients: http://clinicaltrials.gov/show/NCT00721409

Here is a link to the definiton of the drug: http://www.cancer.gov/drugdictionary/?CdrID=454586

Hopeful

Rich66 · 12-08-2009, 02:35 PM

Yeah..well..I guess you have to get in that trial right after recurrence.

Exclusion Criteria:

Prior or concomitant treatment for advanced breast cancer.

Hopeful · 12-08-2009, 02:44 PM

I was just trying to answer your question. Sorry if the information disappointed you.

Hopeful

Rich66 · 12-08-2009, 03:13 PM

No apology necessary. Just trying to get to the immediate utility of the information. Good stuff in the pipeline or with limited accessibility is still good stuff. Ya know..just always want it yesterday

Hopeful · 12-08-2009, 03:41 PM

The day before yesterday would be better . . .

Hopeful